Corneal cross-linking (CXL) with riboflavin (vitamin B2) and UV-A light is a surgical treatment for corneal ectasia, a thinning and bulging of the cornea, in conditions such as keratoconus, pellucid marginal degeneration and post-LASIK ectasia.
Facts
Connections
Treats
Source Corneal cross-linking (Wikipedia)
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundationhttps://en.wikipedia.org/wiki/Corneal_cross-linking, lead sectionQuote, https://en.wikipedia.org/wiki/Corneal_cross-linking, lead section
Corneal cross-linking (CXL) with riboflavin (vitamin B2) and UV-A light is a surgical treatment for corneal ectasia such as keratoconus, PMD, and post-LASIK ectasia.
View the Source 2. Corneal cross-linking (Wikipedia)
History
The technique was first developed in Germany in 1997 by Theo Seiler and his team at the Dresden University of Technology
Treats: Keratoconus, Lead (303352)
Corneal cross-linking (CXL) with riboflavin (vitamin B2) and UV-A light is a surgical treatment for corneal ectasia such as keratoconus, PMD, and post-LASIK ectasia.
View the SourceReader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.
View At A Past Year
Choose a year to see this entry's facts and connections as the atlas records them at that moment: what it held then, what it held instead, and what it had not yet adopted. Choose Present for the current record.